Advanced search
Publication Cover
Expert Opinion on Emerging Drugs Volume 10, 2005 - Issue 1
Submit an article Journal homepage
53
Views
3
CrossRef citations to date
0
Altmetric
Review

Future pharmacological treatment options for nonexudative and exudative age-related macular degeneration

Grant M Comer Indiana University School of Medicine, Department of Ophthalmology, 702 Rotary Circle, Indianapolis, IN 46202, USA. [email protected]
,
Thomas A Ciulla Midwest Eye Institute, Vitreoretinal Service, 201 Pennsylvania Parkway, Indianapolis, IN 46280, USA. [email protected]
,
Jeffery S Heier Ophthalmic Consultants of Boston, Vitreretinal Service, 50 Staniford Street, Suite 600, Boston, MA 02114, USA. [email protected]
&
Mark H Criswell Indiana University School of Medicine, Retina Service Research Laboratories, Department of Ophthalmology, 702 Rotary Circle, Indianapolis, IN 46202, USA. [email protected]
Pages 119-135 | Published online: 22 Apr 2005

Bibliography

  • KAHN H, LEIBOWITZ H, GANLEY J et al.: The Framingham eye study. I. Outline and major prevalence findings. Am. J. Epidemiol. (1977) 106:17–41.
  • ATTEBO K, MITCHELL P, SMITH W: Visual acuity and the causes of visual loss in Australia: the Blue Mountains Eye Study. Ophthalmology (1996) 103:357–364.
  • KLAVER D, WOLFS R, VINGERLING J et al.: Age-specific prevalence and causes of blindness and visual impairment in an older population: the Rotterdam study. Arch. Ophthalmol. (1998) 116:653–658.
  • TIELSCH J, JAVITT J, COLEMAN A et al.: The prevalence of blindness and visual impairment among nursing home residents in Baltimore. N EngL J. Med. (1995) 332:1205–1209.
  • SEDDON J. Epidemiology of age-related macular degeneration. St. Louis: Mosby, (2001) 1039–1050.
  • BIRD A, BRESSLER N, BRESSLER S et al.: An international classification and grading system for age-related maculopathy and age-related macular degeneration. Surv. Ophthalmol. (1995) 39:367–374.
  • AGE-RELATED EYE DISEASE STUDY RESEARCH GROUP: A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch. Ophthalmol. (2001) 119:1417–1436.
  • FLIESLER S, ANDERSON R: Chemistry and metabolism of fluids in the vertebrate retina. Frog. Lipid Res. (1983) 22:79–131.
  • GERSTER H: Review: antioxidant protection of the aging macula. Age Aging (1991) 112:60–69.
  • YOUNG R: Solar radiation and age-related macular degeneration. Surv. Ophthalmol. (1988) 32:252–269.
  • BEATTY S, KOH H, PHIL M et al.: The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv. Ophthalmol. (2000) 45:115–134.
  • NEWSOME D, SWARTZ M, LEONE N et al.: Oral zinc in macular degeneration. Arch. Ophthalmol. (1988) 106: 192–198.
  • THE ALPHA TOCOPHEROL BETA CAROTENE CANCER PREVENTION STUDY GROUP: The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl. J. Med. (1994) 330:1029–1035.
  • MACULAR PHOTOCOAGULATION STUDY GROUP: Argon laser photocoagulation for neovascular maculopathy. Five-year results from randomized clinical trials. Arch. Ophthalmol. (1991) 109:1109–1114.
  • MACULAR PHOTOCOAGULATION STUDY GROUP: Five-year follow-up of fellow eyes of patients with age-related macular degeneration and unilateral extrafoveal choroidal neovascularization. Arch. Ophthalmol. (1993) 111: 1189–1199.
  • MACULAR PHOTOCOAGULATION STUDY GROUP: Argon laser photocoagulation for senile macular degeneration. Arch. Ophthalmol. (1982) 100:912–923.
  • MACULAR PHOTOCOAGULATION STUDY GROUP: Argon laser photocoagulation for neovascular maculopathy; Three-year results from randomized clinical trials. Arch. Ophthalmol. (1986) 104:694–701.
  • FREUND K, YANNUZZI L, SORENSON J: Age-related macular degeneration and choroidal neovascularization. Am. J. Ophthalmol. (1993) 115:786–791.
  • MOISSEIEV J, ALHALEL A, MASURI R, TREISTER G: The impact of the macular photocoagulation study results on the treatment of exudative age-related macular degeneration. Arch. Ophthalmol. (1995) 113:185–189.
  • MACULAR PHOTOCOAGULATION STUDY GROUP: Recurrent choroidal neovascularization after argon laser photocoagulation for neovascular maculopathy. Arch. Ophthalmol. (1986) 104:503–512.
  • MACULAR PHOTOCOAGULATION STUDY GROUP: Subfoveal neovascular lesions in age-related macular degeneration; 'defines for evaluation and treatment in the macular photocoagulation study. Arch. Ophthalmol. (1991) 109:1242–1257.
  • MACULAR PHOTOCOAGULATION STUDY GROUP: Laser photocoagulation of subfoveal neovascular lesions of age-related macular degeneration. Arch. Ophthalmol. (1993)111:1200–1209.
  • AVELINE B, HASEN T, RENARD R: Photochemical and photosensitizing properties of BPD-MA. Photochem. Photobiol. (1994) 59:328–335.
  • HUNT D, JIANG H, GRANVILLE D et al.: Consequences of the photodynamic treatment of resting and activated peripheral T lymphocytes. Immunopharmacology (1999) 41:31–44.
  • ALLISON B, WATERFIELD E, RICHTER A, LEVY J: The effects of plasma lipoproteins on in vivo tumor cell killing and in vivo tumor photosensitization with benzoporphyrin derivative. Photochem. Photobiol. (1991) 54: 709–715.
  • REICHEL E, PULIAFITO C, DUKER J, GUYER D: Indocyanine green dye-enhanced diode laser photocoagulation of poorly defined subfoveal choroidal neovascularization. Ophthalmic. Surg. (1994) 25:195–201.
  • HOPE-ROSS M, GIBSON J, CHELL P et al.: Dye enhanced laser photocoagulation in the treatment of a peripapillary subretinal neovascular membrane. Acta. Ophthalmol. (1994) 72:134–137.
  • MORIARTY A: Indocyanine green enhanced diode laser photocoagulation of subretinal neovascular membranes Br. J. Ophthalmol. (1994) 1994:238–239.
  • TREATMENT OF AGE-RELATED MACULAR DEGENERATION WITH PHOTODYNAMIC THERAPY (TAP) STUDY GROUP: Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials - TAP report. Arch. Ophthalmol. (1999) 117: 1329–1345.
  • TREATMENT Of AGE-RELATED MACULAR DEGENERATION WITH PHOTODYNAMIC THERAPY (TAP) STUDY GROUP: Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials - TAP report 2. Arch. Ophthalmol. (2001) 119:198–207.
  • TREATMENT Of AGE-RELATED MACULAR DEGENERATION WITH PHOTODYNAMIC THERAPY (TAP) STUDY GROUP: Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: three-year results of an open-label extension of 2 randomized clinical trials - TAP Report 5. Arch. Ophthalmol. (2002) 120:1307–1314.
  • VERTEPORFIN IN PHOTODYNAMIC THERAPY (VIP) STUDY GROUP: Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization - Verteporfin in Photodynamic Therapy Report 2. Am. J. Ophthalmol (2001) 131:541–560.
  • BRESSLER N: Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularizaation - Verteporfin in Photodynamic Therapy Report 2. Am. J. Ophthalmol (2002) 133:168–169.
  • NISHIWAKI H, ZEIMER R, GOLDBERG M et al.: Laser targeted photo-occlusion of rat choroidal neovascularization without collateral damage. Photochem. Photobiol. (2002) 75:149–158.
  • GRISANTI S, TATAR O, CANBEK S et al.: Immunohistopathologic evaluation of choroidal neovascular membranes following verteportin photodynamic therapy. Am. J. Ophthalmol (2004) 137:914–923.
  • BONE R, LANDRUM J, TARSIS S: Preliminary identification of the human macular pigment. Vision Res. (1985) 25:1531–1535.
  • BONE R, LANDRUM J, HIME G et al.: Stereochemistry of the human macular pigment. Invest Ophthalmol Vzs. Sci. (1993) 34:2033–2040.
  • MALINOW M, FEENEY-BURNS L, PETERSON L et al.: Diet-related macular anomalies in monkeys. Invest Ophthalmol. lTj Sci. (1980) 19:857–863.
  • NEURINGER M, KLEIN M, SNODDERLY M et al.: Effects of carotenoid depletion and N-3 fatty acid status on macular defects in Rhesus monkeys. Invest Ophthalmol Vis. Sci. (1999) 40(5164):Abstract 842.
  • CIULLA T, CURRAN-CELANTANO J, COOPER D et al: Macular pigment optical density in a midwestern sample. Ophthalmology (2001) 108:730–737.
  • SCHALCH W: Carotenoids in the retina a review of their possible role to prevent or limit damage by light and oxygen. Free Radicals and Aging (1992) 62:280–298.
  • SNODDERLY D, AURAN J, DELORI F: The macular pigment. II. Spatial distribution in primate retinas. Invest Ophthalmol Vis. Sci. (1984) 25:674–685.
  • KATZ M, PARKER K, HANDELMAN G et al.: Effects of antioxidant nutrient deficiency on the retina and retinal pigment epithelium of albino rats: A light and electron microscopic study. Exp. Eye Res. (1982) 34:339–369.
  • SEDDON J, HENNEKES C: Vitamins, minerals, and macular degeneration: Promising but unproven hypotheses. Arch. Ophthalmol (1994) 112: 176–178.
  • SEDDON J, AJANI U, SPERDUTO R et al.: Dietary carotenoids, vitamins A, C, and E, and advanced age-related macular degeneration. Eye Disease Case-Control Study Group/ AMA (1994) 272:1413–1420.
  • WEST S, VITALE S, HALLFRISCH J et al: Antioxidants and supplements: Protective for age-related macular degeneration. Arch. Ophthalmol (1994) 112:222–227.
  • GALE C, HALL N, PHILLIPS D, MARTYN C: Lutein and zeaxanthin status and risk of age-related macular degeneration. Invest Ophthalmol Vis. Sci. (2003) 44:2461–2465.
  • HAMMOND BJ, CIULLA T, SNODDERLY D: Macular pigment density is reduced in obese subjects. Invest Ophthalmol. Vis. Sci. (2002) 43:47–50.
  • SEDDON J, COTE J, DAVIS N, ROSNER B: Progression of age-related macular degeneration association with body mass index, waist circumference, and waist-hip ratio. Arch. Ophthalmol (2003) 121:785–792.
  • MARES-PERLMAN J, BRANDY W, KLEIN R et al.: Serum antioxidants and age-related macular degeneration in a population-based case-control study. Arch. Ophthalmol (1995) 113:1518–1523.
  • CHEW E: Age Related Eye Disease StudyResearch Group. Micronutrient supplementation. American Academy of Ophthalmology Annual Meeting (2004) New Orleans, LA; Retina Subspecialty Day supplement:4.
  • CIULLA T, HARRIS A, KAGEMANN L et al: Choroidal perfusion pertubations in non-neovascular age related macular degeneration. Br. J. Ophthalmol (2002) 86:209–213.
  • CIULLA T, HARRIS A, MARTIN B: Ocular perfusion and age-related macular degeneration. Acta. Ophthalmol Scand. (2001) 79:108–115.
  • CIULLA T, HARRIS A, CHUNG H et al.: Color Doppler imaging discloses reduced ocular blood flow velocities in nonexudative age-related macular degeneration. Am. J. Ophthalmol (1999) 128:75–80.
  • FRIEDMAN E, KRUPSKY S, LANE A et al.: Ocular blood flow velocity in age-related macular degeneration. Ophthalmology (1995) 102:640–646.
  • FRIEDMAN E: A hemodynamic model ofthe pathogenesis of age-related macular degeneration. Am. J. Ophthalmol. (1997) 124:677–682.
  • BOKER T, FANG T, STEINMETZ R: Refractive error and choroidal perfusion characteristics in patients with choroidal neovascularization and age-related macular degeneration. Ger. J. Ophthalmol. (1993) 2:10–13.
  • REMULLA J, GAUDIO A, MILLERS, SANDBERG M: Foveal electroretinograms and choroidal perfusion characteristics in fellow eyes of patients with unilateral neovascular age-related macular degeneration. Br. J. Ophthalmol. (1995) 79:558–561.
  • ZHAO J, FRAMBACH D, LEE P et al.: Delayed macular choriocapillary circulation in age-related macular degeneration. Int. Ophthalmol (1995) 19:1–12.
  • WIDDER R, BRUNNER R, ENGELS B et al.: Changes of hemorheological and biochemical parameters after plasma perfusion using a tryptophan-polyvinyl alcohol adsorber leading to clinical improvement in patients suffering from maculopathy. Blood Purzf (1998) 16: 15–21.
  • BRUNNER R, WIDDER R, WALTER P et al.: Change in hemorrheological and biochemical parameters following membrane differential filtration. Int. J. Artif Organs (1995) 18:794–798.
  • BRUNNER R, WIDDER R, WALTER P et al.: Influence of membrane differential filtration on the natural course of age-related macular degeneration. Retina (2000) 20:483–491.
  • MCGWIN G, OWSLEY C, CURCIO C, CRAIN R: The association between statin use and age related maculopathy. Br. J. Ophthalmol (2003) 87:1121–1125.
  • WILSON H, SCHWARTZ D, BHATT H et al.: Statin and aspirin therapy are associated with decreased rates of chroroidal neovascularization among patients with age-related macular degeneration. Am. J. Ophthalmol (2004) 137:615–624.
  • HALL N, GALE C, SYDDALL H et al.: Risk of macular degeneration in users of statins: cross sectional study. BMJ (2001) 323:375–376.
  • MCCARTY C, MUKESH B, GUYMER R et al.: Cholesterol-lowering medications reduce the risk of age-related maculopathy progression. MJA (2001) 175:340.
  • KLEIN R, KLEIN B, TOMANY S et al.: Relation of statin use to the 5-year incidence and progression of age-related maculopathy. Arch. OphthalmoL (2003) 121:1151–1155.
  • BRESSLER N, ROSENFELD P, LIM J, VIM STUDY GROUP: A Phase II placebocontrolled, double-masked, randomized trial � verteporfin in minimally classic CNV due to AMD (VIM). Invest Ophthalmol. Vis. Sci. (2003) 44:E-abstract 1100.
  • GONZALEZ J: Visudyne benefits patients with minimally classic lesion at 1 year. Ocular Surgery News (2003):21.
  • ROSENFELD P, VIM STUDY GROUP: Verteporfin in minimally classic CNV due to AMD (VIM) - two-year results from a 45:E-abstract 2273.
  • RIDDLE J: PDT: Therapies on the cutting edge. Jobson's Review of Ophthalmology (2003) X(8):40–46.
  • STUR M, VER STUDY GROUP: Verteporfin Early Retreatment (VER) - 12-month results of a Phase IIIB controlled clinical trial. Invest OphthalmoL Vis. Sci. (2004) 45:E-abstract 2275.
  • SLAKTER J, ROSENFELD P, VALIO STUDY GROUP: Verteporfin with altered (delayed) light in occult CNV (VALIO) - Results of a Phase II controlled clinical trial. Invest OphthalmoL Vis. Sci. (2003) 44:E-abstract 1101.
  • SINGERMAN L, ROSENFELD P, VALIO STUDY GROUP: Verteporfin with altered (delayed) light in occult (VALIO) - 12-month results of a Phase II controlled clinical trial. Invest OphthalmoL Vis. Sci. (2004) 45:E-abstract 2274.
  • PEYMAN G, MOSHFEGHI D, MOSHFEGHI A et al.: Photodynamic therapy for choriocapillaris using tin ethyl etiopurpurin (SnET2). Ophthalmic Surg. Lasers (1997) 28:409–417.
  • MOSHFEGHI D, PEYMAN G, MOSHFEGHI A et al.: Ocular vascular thrombosis following tin ethyl etiopurpurin (SnET2) photodymanic therapy: time dependencies. Ophthalmic Surg-. Lasers (1998) 29:663–668.
  • REGILLO C: Update on photodynamic therapy. Curr. Opinion OphthalmoL (2000) 11:166–170.
  • THOMAS E, SnET2 STUDY GROUP: SnET2 photodynamic therapy for age-related macular degeneration: visual acuity efficacy outcomes from two parallel Phase III trials. Invest OphthalmoL Vis. Sci. (2004) 45:E-abstract 2214.
  • BLUMENKRANZ M, MILLER J, GUYER D et al.: Preliminary results from a Phase II dose-response study of photodynamic therapy with motexafin lutetium to treat subfoveal CNV. Invest OphthalmoL Vis. Sci. (2000) 41(5531):abstract 2827.
  • OBANA A. GOHTO Y, KANAI M et al.: Selective photodynamic effects of new photosensitizer ATX-S10(Na) on choroidal neovascularization in monkeys. Arch. OphthalmoL (2000) 118:650–658.
  • RENNO R, TERADA Y, HADDADAIN M et al.: Selective photodynamic therapy by targeted verteporfin delivery to experimental choroidal neovascularization mediated by a homing peptide to vascular endothelial growth factor rectptor-2. Arch. OphthalmoL (2004) 122:1002–1011.
  • ISHIBASHI T, MIKI K, SORGENTE N et al.: Effects of intravitreal administration of steroids on experimental subretinal neovascularization in the subhuman primat. Arch. OphthalmoL (1985) 103: 708–711.
  • KVANTA A: Expression and regulation of vascular endothelial growth factor in choroidal fibroblasts. Curr. Eye Res. (1995) 14:1015–1020.
  • AMIN R, PUKLIN J, FRANK R: Growth factor localization in choroidal neovascular membranes of age-related macular degeneration. Invest OphthalmoL Vis. Sci. (1994) 35:3178–3188.
  • LOPEZ P, SIPPY B, LAMBERT H et al.: Transdifferentiated retinal pigment epithelia cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest OphthalmoL Vis. Sci. (1996) 37:855–568.
  • REDDY V, ZAMORA R, KAPLAN H: Distribution of growth factors in subfoveal neovascular membranes in age-related macular degeneration and presumed ocular histoplasmosis syndrome. Am. J. OphthalmoL (1995) 120:291–301.
  • YI X, OGATA N, KOMADA M et al.: Vascular endothelial growth factor expression in choroidal neovascularization in rats. Graefis Arch. Clin. Exp. OphthalmoL (1997) 235:313–319.
  • OKAMOTO N, TOBE T, HACKETT S et al.: Transgenic mice with increased expression of vascular endothelial growth factor in the retina: a new model of intraretinal and subretinal neovascularization. Am. J. PathoL (1997) 151:281–291.
  • ADAMIS A, SHIMA D, TOLENTINO M et al.: Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch. OphthalmoL (1996) 114:66–71.
  • AIELLO L, PIERCE E, ED F et al.: Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc. NatL Acad. Sci. USA (1995) 92:10457–10461.
  • THE EYETECH STUDY GROUP: Preclinical and Phase Ia clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina (2002) 22:143–152.
  • THE EYETECH STUDY GROUP: Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration - Phase II study results. Ophthalmology (2003) 110:979–986.
  • GRAGOUDAS E: VEGF Inhibition Study in Ocular Neovascularization-1 (VISION-1): efficacy redulst from Phase II/III Macugen (pegaptanib sodium) clinical trials [abstract]. Invest OphthalmoL Vis. Sci. (2004) 45(E-abstract 2364).
  • SCHWARTZ S: Anti-VEGF: Eyetech - Macugen. American Academy of Ophthalmology Annual Meeting (2004) New Orleans, LA; Retina Subspecialty Day supplement:35–7.
  • D'AMICO D, BIRD A: VEGF Inhibition Study in Ocular Neovascularization-1 (VISION-1): safety evaluation from the pivotal MacugenTm (pegaptanib sodium) clinical trials [abstract]. Invest OphthalmoL Vis. Sci. (2004) 45:E-abstract 2363.
  • ROACH L: Macugen ups the anti-AMD ante. Eyenet (2004) :29–30.
  • HEIER J, SY J, MCCLUSKEY E, RHUFAB V2 STUDY GROUP: RhuFab V2 in wet AMD -6 month continued improvement following multiple intravitreal injections. Invest Ophthalmol. Ws. (2003) 44:E-abstract 972.
  • HEIER J: Anti-VEGF: Genentech-Ranibizumab. American Academy of Ophthalmology Annual Meeting (2004) New Orleans, LA; Retina Subspecialty Day supplement:38.
  • GUTTMAN C: Phase III study eyes intravitreal therapy for exudative AMD. Ophthalmology Times (2004) 29(13):40–41.
  • HOLASH J, DAVIS S, PAPADOPOULOS N et al.: VEGF-Trap: a VEGF blocker with potent antitumor effects. PNAS (2002) 99:11393–11398.
  • SAISHIN Y, SAISHIN Y, TAKAHASHI K et al.: VEGF-TRAP R1R2 suppresses chroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier. J. Cell. PhysioL (2003) 195:241–248.
  • TOLENTINO M, BRUCKER A, FOSNOT J et al.: Intravitreal injection of vascular endothelial growth factor small interfering RNA inhibits growth and leakage in nonhuman primate laser induced model of choroidal neovascularization. Retina (2004) 24:132–138.
  • REICH S, FOSNOT J, KUROKI A et al.: Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. MoL Vis. (2003) 9:210–216.
  • HOLEKAMP N, BOUCK N, VOLPERT O: Pigment epithelium-derived factor is deficient in the vitreous of patients with choroidal neovascularization due to age-related macular degeneration. Am. J. Ophthalmol. (2002) 134:220–227.
  • TAKITA H, YONEYA S, GEHLBACK P et al.: Retinal neuroprotection against ischemic injury mediated by intraocular gene transfer of pigment epithelium derived factor. Invest Ophthalmol. Vis. Sci. (2003) 44:4497–4504.
  • STELLMACH V, CRAWFORD S, ZHOU W, BOUCK N: Prevention of ischemia-induced retinopathy by the natural ocular antiangiogenic agent pigment epithelium-derived factor. Proc. NatL Acad. Sci. USA (2001) 98:2593–2597.
  • MORI K, DUH E, GEHLBACK P et al.: Pigment epithelium-derived factor inhibits retinal and choroidal neovascularization. J. Cell. Invest. (2001) 188:253–263.
  • RASMUSSEN H, CHU K, P C et al.: Clinical protocol. An open-label, Phase I, single administration dose-escalation study of ADGVPEDF.11D (ADPEDF) in neovascular age-related macular degeneration (AMD). Hum. Gene Ther. (2001) 12:2029–2032.
  • CAMPOCHIARO P, KLEIN M, HOLTZ E et al.: AdPEDF therapy for subfoveal choroidal neovascularization (CNV): preliminary Phase I results. Invest. Ophthalmol. Vis. Sci. (2004) 45:E-abstract 2361.
  • LEAHY K, ORNBERG R, WANG Y et el.: Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res. (2002) 62:625–631.
  • GENAIDY M, KAZI A, PEYMAN G et al.: Effect of squalamine on iris neovascularization in monkeys. Retina (2002) 22:772–778.
  • HIGGINS R, SANDERS R, YAN Y et al.: Squalamine improves retinal neovascularization. Invest Ophthalmol. Vis. Sci. (2000) 41:1507–1512.
  • CIULLA T, CRISWELL M, DANIS R et al.: Squalamine lactate reduces choroidal neovascularization in a laser-injury model in the rat. Retina (2003) 23:808–814.
  • WOESNNER J: The matrix metalloproteinase family. Academy Press, San Diego (1998) :1–14.
  • MATRISIAN L. Metalloproteinases and their inhibitors in matrix remodeling: Review. Trends Genet. (1990) 6:121–125.
  • ANAND-APTE B, PEPPER M, VOEST E et al.: Inhibition of angiogenesis by tissue inhibitor of metalloproteinase-3. Invest Ophthalmol. Vis. Sci. (1997) 38:817–823.
  • STEEN B, SEJERSEN S, BERGLIN L et al.: Matrix metalloproteinases and metalloproteinase inhibitors in choroidal neovascular membranes. Invest Ophthalmol. Vis. Sci. (1998) 39:2194–2200.
  • FARIS R, APTE S, OLSEN B et al.: Tissue inhibitor of metalloproteinases-3 is a component of Bruch's membrane of the eye. Am. J. PathoL (1997) 150:323–328.
  • KAMEI M, HOLLEYFIELD J: TIMP-3 in Bruch's membrane: change during aging and in age-related macular degeneration. Invest Ophthalmol. Vis. Sci. (1999) 40:2367–2375.
  • OZERDEM U, MACH-HOFACRE B, VARKI N et al.: The effect of prinomastat (AG2240), a synthetic inhibitor of matrix metalloproteinases, on uveal melanoma rabbit model. Curr. Eye Res. (2002) 24:86–91.
  • OZERDEM U, MACH-HOFACRE B, KEEFE K et al.: The effect of prinomastat (AG3340), a synthetic inhibitor of matrix metalloproteinases, on posttraumatic proliferative vitreoretinopathy. Ophthalmic Res. (2001) 33:20–23.
  • CHENG L, RIVERO M, GARCIA C et al.: Evaluation of intraocular pharmacokinetics and toxicity of prinomastat (AG3340) in the rabbit. J. Ocular. Pharm. Ther. (2001) 17:295–304.
  • ZHANG K, MCDERMOTT C, BREKKEN J et al.: Ocular bioavailability and pharmacokinetics of AG3340, a potent MMP inhibitor with antiangiogenic activity, following oral administration. Proc. NY Acad. Sci.. Tampa, FL, (1998).
  • COLLIER M, YUEN B, BANSAL S et al.: Phase I study of the matrix metalloprotease inhibitor AG3340 given in a single dose to healthy volunteers. Proc. Am. Assoc. Cancer Res. (1997) 38:A1491.
  • GARCIA C, BARTSCH D, RIVERO M et al.: Efficacy of prinomastat (AG3340), a matrix metalloprotease inhibitor, in treatment of retinal neovascularization. Curr. Eye Res. (2002) 24:33–38.
  • NAMBU H, NAMBU R, MELIA M, CAMPOCHIARO P: Combretastatin A-4 phosphate suppresses development and induces regression of choroidal neovascularization. Invest. Ophthalmol. Sci. (2003) 44:3650–3655.
  • FOLKMAN J, INGBER D: Angiostatic steroids. Ann. Surg (1987) 206:374–382.
  • OHKUMA H, RYAN S: Experimental subretinal neovascularization in the monkey. Permeability of new vessels. Arch. Ophthalmol. (1983) 101:1102–1110.
  • SCHLAEGEL T: Ocular Histoplasmosis. Grund & Stratton, New York (1977).
  • MARTIDIS A, MILLER D, CIULLA T et al.: Corticosteroids as an antiangiogenic agent for histoplasmosis-related subfoveal choroidal neovascularization. J. Ocular. Pharm. Ther. (1999) 15:425–428.
  • CIULLA T, CRIS WELL M, DANIS R, HILL T: Intravitreal triamcinolone acetonide inhibits choroidal neovascularization in a laser-treated rat model. Arch. Ophthalmol. (2001) 119:399–404.
  • DANIS R, BINGAMAN D, YANG Y, LADD L: Inhibition of preretinal and optic nerve head neovascularization in pigs by intravitreal triamcinolone acetonide. Ophthalmology (1996) 103:2099–2104.
  • PENFOLD P, GYORY J, HUNYOR A, BILLSON F: Exudative macular degeneration and intravitreal triamcinolone. A pilot study. Aust. N Zeal. J. Ophthalmol. (1995) 23:293–298.
  • DANIS R, CIULLA T, PRATT L et el.: Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina (2000) 20:244–250.
  • RANSON N, DANIS R, CIULLA T, PRATT L: Intravitreal triamcinolone in subfoveal recurrence of choroidal neovascularisation after laser treatment in macular degeneration. Br. J. Ophthalmol. (2002) 86:527–529.
  • CHALLA J, GILLIES M, PENFOLD P et al.: Exudative macular degeneration and intravitreal triamcinolone: 18 month follow up. Aust. IV. Zeal. J. Ophthalmol. (1998) 26:277–281.
  • GILLIES M, SIMPSON J, LUO W et al.: A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration. Arch. Ophthalmol. (2003) 121:667–673.
  • SPAIDE R, SORENSON J, MARANAN L: Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization. Ophthalmology (2003) 110:1517–1525.
  • HERIOT W: Corticosteroids for AMD. American Academy of0phthalmology Annual Meeting (2004) New Orleans, LA; Retina Subspecialty Day supplement:24–25.
  • MOSHFEGHI D, KAISER P, SCOTT I et al.: Acute endophthalmitis following intravitreal triamcinolone acetonide injection. Am. J. Ophthalmol. (2003) 136:791–796.
  • JONAS J, KREISSIG I, HUGGER P et al.: Intravitreal triamcinolone acetonide for exudative age-related macular degeneration. Br. J. Ophthalmol. (2003) 87(462–8).
  • JONAS J, KREISSIG I, DEGENRING R: Intraocular pressure after intravitreal injection of triamcinolone acetone. Br. J. Ophthalmol. (2003) 87:24–27.
  • CRUM R, SZABO S, FOLKMAN J: A new class of steroids inhibits angiogenesis in the presence of heparin or heparin fragment. Science (1995) 230:1375–1378.
  • CLARK A: AL-3789: a novel ophthalmic angiostatic steroid. Expert Opin. Investig. Drugs (1997) 6:1867–1877.
  • MCNATT L, WEIMER L, YANNI J, CLARK A: Angiostatic activity of steroids in the chick embryo CAM and rabbit cornea models of neovascularization. Ocular Pharm. Ther. (1999) 15:413–423.
  • THE ANECORTAVE ACETATE CLINICAL STUDY GROUP: Anecortave acetate as monotherapy for the treatment of subfoveal lesion in patients with exudative age-related macular degeneration (AMD) - interim (month 6) analysis of clinical safety and effecacy. Retina (2003) 23:14–23.
  • CLARK A, MELLON J, Li X et el.: Inhibition of intraocular tumor growth by topical application of the antiangiogenic steroid anecortave acetate. Invest Ophthalmol. Vis. Sci. (1999) 40:2158–2162.
  • PENN J, RAJARATNAM V, COLLIER R, CLARK A: The effect of an angiostatic steroid on neovascularization in a rat model of retinopathy of prematurity. Invest Ophthalmol. Vis. Sci. (2001) 42:283–290.
  • THE ANECORTAVE ACETATE CLINICAL STUDY GROUP: Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in age-related macular degeneration - twelve month clinical outcomes. Ophthalmology (2003) 110:2372–2383.
  • CIULLA T, CRISWELL M, DANIS R et al.: Choroidal neovascular membrane inhibition in a laser treated rat model with intraocular sustained release triamcinolone acetonide microimplants. Br. J. Ophthalmol. (2003) 87:1032–1037.
  • NADER N: Clinical trials show promise of intravitreal steroids, other therapies for retinal diseases. Ocular Surgery News (2004) 22(3):28–30.
  • YANG C, KHAWLY J, HAINS WORTH D et al.: An intravitreal sustained release triamcinolone and 5-fluorouracil codrug in the treatment of experimental proliferative vitreoretinopathy. Arch. Ophthalmol. (1998) 116:69–77.
  • PERKINS S, GALLEMORE R, YANG C et al.: Pharmacokinetics of the fluorcinolon/ 5-fluorouracil codrug in the gas-filled eye. Retina (2000) 20:514–519.

Websites

  • http://www.us.novartisophthalmics.com/ hcp/press-release/Visodyne_E_10.05.pdf Accessed 10/15/2004 VISUDYNE: launched in Japan for treatment of age-related macular degeneration [Press release dated 10/5/2004] [online].
  • http://www.qltinc.com/Qltinc/main/ mainpages.cfm?InternetPageID=143, ed Accessed 4/29/2004. QLT, Inc. Occult AMD.
  • http://www.cms.hhs.gov/medlearn/matters/ mmarticles/ 192004/MM3191.pdf Accessed 4/29/2004. Centers for Medicare and Medicaid Services.
  • http://www.retinal-research.org/ study_descriptions.htmlvisudyne Accessed 10/23/2003. Study compares early versus standard visudyne therapy for AMD. LuEsther T. Mertz Retinal Research Center.
  • http://www.miravant.com/Pages/ News_Center/News_Center_Frameset.htm Accessed 10/15/2004. MIRAVANT announces PHOTREX as new brand name for SnET2 PDT [press release dated 10/6/2004].
  • http://www.pharmacyclics.com/ webpage_templates/ tert.php3?page_name=pr_1 004643211 Accessed 9/24/2003. Pharmacyclics regains rights to Optrin from Alcon. Pharmacyclics, Inc.
  • http://www.lightsciences.com/news/ investnw.html Accessed 10/15/2004 Light Sciences to present Seattle's Invest Northwest Converence [press release dated 3/17/2004].
  • http://www.eyetk.com/clinical/ clinical_index.asp Accessed 9/25/2003 Eyetech pharmaceuticals, Inc. clinical trials. Eyetech Pharmaceuticals, Inc.
  • http://www.eyetech.com/investors/ Press_Releases.asp Accessed 10/12/2004 Pfizer and Eyetech provide regulatory update on Macugen - pegaptanib sodium injection [press release dated 9/20/2004].
  • http://www.macular.org/news/clinical/ rhufab.html Accessed 9/25/2003 Genentech announces preliminary positive Phase lb/II data for rhuFab V2 in age-related macular degeneration. Genentech, Inc.
  • http://www.regeneron.com/investor/ press_detail.asp?v_c_id=194 Accessed 10/29/2004 Regeneron Pharmaceuticals. Initial Phase I study will evaluate safety and tolerability of VEGF Trap in patients with age-related macular degeneration [press release dated 3/9/2004].
  • http://www.acuitypharma.com/page5.html Accessed 10/6/2004. Acuity Pharmaceuticals. Acuity Pharmaceuticals announces first-ever IND for therapeutic RNAi [press release dated 8/10/2004].
  • http://www.acuitypharma.com/page5.html Accessed 10/7/2004 Acuity Pharmaceuticals. Acuity Pharmaceuticals closes $15 million financing and initiates first ever clinical trial of an RNAi therapeutic [press release dated 10/7/2004].
  • http://www.sirna.com/index/html Accessed 10/7/2004 Sirna Therapeutics, Inc. Sirna Therapeutics' first IND filing applies novel RNAi therapy to the treatment of age-related macular degeneration [press release dated 9/7/2004].
  • http://www.corporateirmedireye/ ir_site.zhtml?ticker=GNVC6cscript=4106c1 ayout=66citem_id=600931 Accessed 9/28/2004 GenVec, Inc. GenVec announces 2nd quarter 2004 financial results and updates on clinical programmes [press release dated 8/5/04].
  • http://www.clinicaltrials.gov/ct/show/ NCT00043680) Accessed 10/12/2004. Celecoxib to treat macular degeneration in patients receiving photodynamic therapy.
  • http://www.genaera.com/pressreleases/192003_oct7.html Accessed 10/11/2003 Genaera reports squalamine continues to improve vision at four months timepoint in age-related macular degeneration. Genaera Corp. [press release dated 10/7/2003].
  • http://www.genaera.com/pressreleases/ October°/0204,°/0202004.pdf Accessed 10/7/2004. Genaera Corporation. Genaera receives FDA Fast Track status for squalamine in macular degeneration [press release dated 10/4/04].
  • http://www.oxigene.com/press/ pressreleases.asp) Accessed 10/7/2004 OXiGENE, Inc. OXiGENE announces interim results of wet age-related macular degeneration trial of Combretastatin A4 Prodrug [press release dated 5/18/04].
  • http://www.nature.com/cgitaf/ DynaPage.taf?file=/eye/journal/vaop/ ncurrent/abs/6701438a.html Accessed 10/7/2004. JONAS J, DEGENRING R, KREISSIG I et al.: Exudative age-related macular degeneration treated by intravitreal triamcinolone acetonide. A prospective comparative nonrandomized study [advanced online publication]. Eye (2004).
  • http://wwwl.regenera.com.au/Uploacl/ docsAustralian_Biotechnology_News_Artic le_-_13_aug_04.pdf Accessed 10/7/2004 TRUDINGER M: Regenera sees new application for technology [online]. Australian Biotechnology News (2004).
  • http://vocuspr.vocus.com/VocusPR30/ Temp/Sites/2145/04-06-30%2ORETAANE°/020NDA9/020Release°/0 20E-mail.doc Accessed 10/10/2004. REGILLO C, JERDAN J: Anecortave acetate: prevention of AMD. American Academy of Ophthalmology Annual Meeting Retina Subspecialty Day supplement (2004) :10-11. Alcon, Inc. Alcon updates filing status of RETAANE® New Drug Application. [press release dated 6/30/04].
  • http://vocuspr.vocus.com/VocusPR30/ Temp/Sites/2145/ Risk°/020Reduction°/020Tria10/020Release°/0 20Final°/020E-mail.doc Accessed 10/12/2004. Alcon, Inc. Alcon to initiate new anecortave acetate clinical trials for age-related macular degeneration [press elease dated 11/13/03].
  • http:www.controldelivery.com/ PRMay 72003.htm Accessed 10/7/2004. CONTROL DELIVERY SYSTEMS: Analysis of 12-month data from diabetic macular edema clinical trail sponsored by Bausch & Lomb and Control Delivery Systems to be presented at ARVO 2003 [press release dated 5/7/2003].
  • http://www.clinicaltrials.gov/ct/show/ NCT00032396 Accessed 10/10/2004. Clinical Trials.gov. A study to evaluate Retisert in the treatment of patients with the 'wet' form of age-related macular degeneration.
  • http://www.prnewswire.com/cgibin/ micro_stories.pl?ACCT=1465496cTICK= OCLX&STORY=/www/story/05-08-2003/ 00019429106cEDATE=May+8,+2003. Accessed 10/5/2003. Oculex announces positive clinical results for Posurdes (R) - The first biodegradable ocular implant in clinical trial [Press released dated 5/8/2003].

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.